(Philadelphia,
PA) - Yassine Amrani, PhD, has been appointed
Research Assistant Professor in the Department of Medicine,
Division of Pulmonary, Allergy and Critical Care, at
the University of Pennsylvania School of Medicine.
Dr. Amrani holds a Masters of Science degree in Cellular
Biology from the University of Constantine in Algeria
and earned a Masters of Science degree in Pharmacology,
as well as a Doctor of Philosophy degree in Pulmonary
Pharmacology, from the University of Strasbourg I in
France.
His primary research focuses on understanding the cellular
and molecular mechanisms that regulate bronchial hyper-responsiveness,
a defining characteristic of allergic asthma. Dr. Amrani
was amongst the first in the field to suggest that abnormalities
in airway smooth muscle, an important tissue in regulating
the bronchomotor tone in healthy conditions, may play
an important role in the development of the non-specific
bronchial hyper-responsiveness in asthma to pharmacological
agents. These findings showed that targeting airway
smooth muscle may serve as a new potential therapeutic
approach for the treatment of chronic lung diseases.
Dr. Amrani's research is supported by the Parker B.
Francis Fellowship for Pulmonary research and grants
from the American Lung Association and the National
Institutes of Health. His research has been published
in the European Journal of Pharmacology, the
British Journal of Pharmacology, the American
Journal of Respiratory Cell and Molecular Biology,
the Faseb Journal, the Journal of Clinical
Investigation and the Journal of Immunology,
among others.
Dr. Amrani is a member of the American Society for Pharmacology
and Experimental Therapeutics and the American Association
of Immunologists. He is an ad-hoc reviewer for many
journals including the American Journal of Physiology
and the Journal of Immunology. Among his many
accolades, he has received Fellowship Awards from the
Association Claude Bernard, the Fondation pour la Recherche
Médicale, and the Association Francaise pour
la Recherché Thérapeutique, all in Paris,
France.
# # #
.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.